Ulcerations with Janus Kinase inhibitors: A case/non-case study in VigiBase®

被引：0
|
作者：
De Nardo, C. [1 ]
Turpin, A. [1 ]
Pinel, S. [1 ]
机构：
[1] Ctr dInvest Clin, CRPV St Louis, INSERM CIC 142, 1 Ave Claude Vellefaux, Paris, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
Ruxolitinib; Baricitinib; Tofacitinib; Upadacitinib; Filgotinib; Fedratinib; JAK inhibitors; ulceration;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-033
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [1] Angiotensin receptor blockers induced cough: a case/non-case study in VigiBase®
    Humbert, X.
    Chretien, B.
    Sassier, M.
    Fedrizzi, S.
    Alexandre, J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 44 - 44
  • [2] The Impact of Age and Gender on Reporting of Cough and Angioedema with RAS Inhibitors: A Case/Non-Case in VigiBase
    Alharbi, Fawaz F.
    Kholod, Anzhelika A. V.
    Souverein, Patrick C.
    Meyboom, Ronald H.
    Groot, Mark C. H.
    De Boer, Anthonius
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 443 - 443
  • [3] WEIGHT GAIN AND ANTIPSYCHOTICS. A CASE/NON-CASE APPROACH IN VIGIBASE
    Treceno, C.
    Jimeno, N.
    Martin, L.
    Sainz, M.
    Salado, I
    Garcia, P.
    Velasco, V.
    Carvajal, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 8 - 8
  • [4] What fluoroquinolones have the highest risk of aortic aneurysm? A case/non-case study in VigiBase®
    Sommet, A.
    Benevent, J.
    Rousseau, V.
    Chebane, L.
    Montastruc, J. L.
    Montastruc, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 42 - 42
  • [5] What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®
    Agnès Sommet
    Justine Bénévent
    Vanessa Rousseau
    Leila Chebane
    Antonios Douros
    Jean-Louis Montastruc
    François Montastruc
    Journal of General Internal Medicine, 2019, 34 : 502 - 503
  • [6] What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®
    Sommet, Agnes
    Benevent, Justine
    Rousseau, Vanessa
    Chebane, Leila
    Douros, Antonios
    Montastruc, Jean-Louis
    Montastruc, Francois
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (04) : 502 - 503
  • [7] FACIAL PARALYSIS AND VACCINES. A CASE NON-CASE APPROACH IN VIGIBASE AND IN VAERS
    Jimenez, A.
    Feas, N.
    Rodriguez, M.
    Sainz, M.
    Arias, L. M.
    Carvajal, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 16 - 16
  • [8] Venous thromboembolism and Janus-kinase inhibitors: a Vigibase® study
    Lepelley, M.
    Khouri, C.
    Valnet-Rabier, M. B.
    Baillet, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 69 - 70
  • [9] METAMIZOL-INDUCED AGRANULOCYTOSIS: A CASE/NON-CASE STUDY OF SUSPECTED ADVERSE DRUG REACTIONS IN VIGIBASE
    Treceno, C.
    Velasco, V.
    Jimenez Serrania, M., I
    Martin Arias, L. H.
    Ibanez, L.
    Molokhia, M.
    Carvajal, A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 36 - 36
  • [10] Drug-induced vitiligo: a case/non-case study in Vigibase(R), the WHO pharmacovigilance database
    Anthony, Norah
    Bourneau-martin, Delphine
    Ghamrawi, Sarah
    Lagarce, Laurence
    Babin, Marina
    Briet, Marie
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (06) : 736 - 742
12345